Travere Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppre...
Latest News
12 hours ago · seekingalpha.com
Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptTravere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
17 hours ago · seekingalpha.com
Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling BuyTravere Therapeutics has achieved two significant FDA approvals for FILSPARI, driving notable revenue growth. TVTX shares have nearly tripled since the initial 'Buy' rating in August 2025, reflecting strong momentum. With two FDA-approved revenue streams, TVTX now faces questions about sustaining its exceptional upward trajectory.
13 days ago · businesswire.com
Travere Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ETStifel 2026 Healthcare ConferencePresenting on Wednesday, November 11, 2026, at 3:20 p.m. ETUBS Global Biopharma ConferencePresenting on Monday, November 16, 2026, at 11:20 a.m. GMTJefferies London Healthcare ConferencePresenting.
14 days ago · seekingalpha.com
Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call TranscriptTravere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript
14 days ago · zacks.com
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 EarningsThe headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
14 days ago · marketbeat.com
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings CallTravere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney-disease and rare-disease pipeline.
14 days ago · zacks.com
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue EstimatesTravere Therapeutics (TVTX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $0.28 per share a year ago.
14 days ago · businesswire.com
Travere Therapeutics Reports Third Quarter 2026 Financial ResultsSAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “We remain early in reaching the more than 100,000 a.
21 days ago · businesswire.com
Travere Therapeutics to Report Third Quarter 2026 Financial ResultsSAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. F.
24 days ago · businesswire.com
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathySAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO.“These biomarker data provide new insight into how FILSPARI's dual mechanism of action may modify the unde.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TVTX